Renal cell carcinoma: Evolving and emerging subtypes

Suzanne M Crumley, Mukul Divatia, Luan Truong, Steven Shen, Alberto G Ayala, Jae Y Ro

Abstract

Our knowledge of renal cell carcinoma (RCC) is rapidly expanding. For those who diagnose and treat RCC, it is important to understand the new developments. In recent years, many new renal tumors have been described and defined, and our understanding of the biology and clinical correlates of these tumors is changing. Evolving concepts in Xp11 translocation carcinoma, mucinous tubular and spindle cell carcinoma, multilocular cystic clear cell RCC, and carcinoma associated with neuroblastoma are addressed within this review. Tubulocystic carcinoma, thyroid-like follicular carcinoma of kidney, acquired cystic disease-associated RCC, and clear cell papillary RCC are also described. Finally, candidate entities, including RCC with t(6;11) translocation, hybrid oncocytoma/chromophobe RCC, hereditary leiomyomatosis and RCC syndrome, and renal angiomyoadenomatous tumor are reviewed. Knowledge of these new entities is important for diagnosis, treatment and subsequent prognosis. This review provides a targeted summary of new developments in RCC.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Renal cell carcinoma; Subtypes; Xp11 translocation; Mucinous tubular and spindle cell; Multilocular cystic clear cell; Carcinoma associated with neuroblastoma recently described entities; Clear cell papillary renal cell carcinoma; Acquired cystic kidney disease; Hereditary leiomyomatosis; Candidate entities; Renal cell carcinoma with t(6;11) translocation

Core tip: New concepts in selected renal cell carcinoma (RCC) subtypes are reviewed. We describe evolving concepts in Xp11 translocation carcinoma, mucinous tubular and spindle cell carcinoma, multilocular cystic clear cell RCC, and carcinoma associated with neuroblastoma. Additionally, tubulocystic carcinoma, thyroid-like follicular carcinoma of kidney, acquired cystic disease-associated RCC, and clear cell papillary RCC are described. Finally, candidate entities, including RCC with t(6;11) translocation, hybrid oncocytoma/chromophobe RCC, hereditary leiomyomatosis and RCC syndrome, and renal angiomyoadenomatous tumor are discussed. This review provides a targeted summary of recent updates for those who diagnose and treat renal cancer.

Crumley SM, Divatia M, Truong L, Shen S, Ayala AG, Ro JY. Renal cell carcinoma: Evolving and emerging subtypes. World J Clin Cases 2013; 1(9): 262-275 Available from: URL: http://www.wjgnet.com/2307-8960/full/v1/i9/262.htm DOI: http://dx.doi.org/10.12998/wjcc.v1.i9.262

INTRODUCTION

Many new discoveries have been made with regards to renal cell carcinoma (RCC) in recent years. At the recent meeting of the International Society of Urologic Pathology, the newly defined, recently described, and candidate entities within RCC were discussed. An understanding of these new subtypes is essential for the surgical
pathologist and urologist. An awareness of the current knowledge among these physicians will enable effective communication for proper diagnosis, prognosis, and treatment.

The five traditional and well-defined subtypes of RCC (conventional clear cell, papillary, chromophobe, collecting duct, and unclassified) comprise the overwhelming majority of RCC, but will not be discussed in detail here. In this review, we discuss three categories of evolving and emerging entities of renal tumors. The first category includes the newly defined RCC subtypes, the second includes recently described entities and the final category includes candidate entities for RCC subtypes (Table 1). The category of recently described tumors includes neoplasms with accruing evidence that they should be considered independent subtypes. The category of candidate entities includes both renal carcinomas seen in familial cancer syndromes and neoplasms on which there is still speculation as to whether they deserve designation as distinct entities. The tumors within all three categories have received much scrutiny in recent years with important updates.

**NEWLY DEFINED RCC SUBTYPES**

**Xp11 translocation carcinoma**

Xp11 translocation RCC was first established by the World Health Organization (WHO) as an independent subtype in 2004[1]. This tumor is defined by a translocation involving the TFE3 gene with various gene partners, the most common of which are ASPL and PRCC. The name Xp11 translocation RCC comes from the chromosomal location of the TFE3 gene (specifically Xp11.2). The tumor is defined by both papillary and clear cell morphology. These tumors can also have a nested architecture, and the type (location) of gene translocation may be reflected in the tumor morphology. ASPL-TFE3 translocation carcinomas have more abundant cytoplasm and frequent psammoma bodies, while PRCC-TFE3 translocations have less cytoplasm, less frequent psammoma bodies, and closely nested tumor cells[2]. In general, these tumors have voluminous, clear to eosinophilic cytoplasm, and well-defined cell borders[3-4] (Figure 1). Cystic change, psammoma bodies, spindle cells, giant cells, and biphasic appearance have been described[5,6]. Grossly, they appear similar to clear cell RCC. Xp11 translocation RCC has traditionally been described as occurring more frequently in young adults and children. Recent reports speculate whether these carcinomas may be associated with chemotherapy[7].

These tumors are typically negative for cytokeratin and positive for CD10, RCC marker, vimentin, PAX2, and PAX8[5-8]. A strongly positive nuclear stain for the C-terminal of the TFE3 gene product is indicative of Xp11 translocation RCC. However, recently, some have questioned the specificity of the TFE3 staining. A recent series by Klatte et al[8] examined 848 patients over a 20-year period and found 75 RCCs with features morphologically consistent with Xp11 translocation RCC or occurring in patients 40 years or younger. Of these 75 tumors, 17 (23%) tumors had strong nuclear TFE3 expression. However, only two of these cases had a translocation detected by FISH, yielding a dismal positive predictive value of 12%. This study suggests that the TFE3 immunohistochemical stain can also stain non-translocated TFE3 product. The average age of patients with RCC positive for TFE3 immunohistochemical staining in this study was 33.4 years. Interestingly, this study also found that strong TFE3 expression in both non-translocated and translocated tu-

### Table 1 Renal cell carcinoma subtypes

| Renal cell carcinoma | Newly defined subtypes | Recently described entities | Candidate entities |
|----------------------|------------------------|-----------------------------|--------------------|
|                      | Xp11 Translocation RCC | Tubulocystic carcinoma      | RCC with t(6;11) translocation |
|                      | Mucinous tubular and spindle cell carcinoma | Thyroid-like follicular carcinoma of kidney | Hybrid oncocyto/a/chromophobe RCC |
|                      | Multilocular cystic clear cell RCC | Acquired cystic kidney disease-associated RCC | Hereditary leiomyomatosis and RCC syndrome |
|                      | Carcinoma associated with Neuroblastoma | Clear cell papillary RCC | Renal angiomyoadenomatous tumor |

RCC: Renal cell carcinoma.

---

*Figure 1  Xp11 translocation carcinoma (hematoxylin and eosin). A: The tumor is composed of cells with clear to eosinophilic, abundant voluminous cytoplasm (×40); B: Psammoma bodies in stromal hyaline nodules are frequently seen, but are not required for diagnosis (×100); C: TFE3 nuclear immunohistochemical stain can assist with confirmation of the diagnosis (×100), but can also be positive in tumors without the molecular translocation.*
mors was associated with larger tumor size, lymph node involvement, and metastasis[8]. Positive TFE3 staining was also associated with worse survival in univariate analysis ($P = 0.032$), albeit this was not significant in multivariate analysis ($P = 0.404$). This evidence suggests that strong TFE3 immunohistochemical staining in adults may be informative for prognosis as well as diagnosis.

Traditionally, Xp11 translocation carcinoma is described primarily in children and young adults. However, recent studies have suggested the presence of these tumors in adults may go unrecognized. A recent study by Zhong et al[9] of 121 consecutive RCCs from 2001-2009 in adults at one institution found 6 tumors with Xp11 translocation for a frequency of 5%[9]. While in pediatric RCC, Xp11 translocation RCC has been found in up to one third of all tumors[3], RCC, in general, is much more frequent in adults than in children. Therefore, the majority of Xp11 translocation RCC may occur in the adult population. Additionally, in adults, these tumors may behave more aggressively and have an association with the female gender. Xp11 translocation RCC in adults has been found to present with advanced stage, lymph node metastases, and have a poor survival rate. A recent commentary by Klaassen et al[10] in the Journal of Urology suggests that adult patients with Xp11 translocation RCC should be classified as high risk for metastasis. They suggest these patients should follow a vigilant surveillance protocol, which includes lifelong follow-up after diagnosis[10].

The differential diagnosis for Xp11 translocation RCC includes clear cell RCC, clear cell papillary RCC, papillary RCC (especially type 2), and the closely related translocation 6;11 carcinoma (discussed below). The TFE3 translocation is diagnostic for tumors with overlapping morphology. The diagnosis of Xp11 translocation RCC should be investigated in children and young-to-middle-aged adults with characteristic histology that is negative for cytokeratins[9]. New evidence suggests that if the classic morphology is present, the diagnosis should also be considered in adults. Based on these clinicopathologic features, we recommend a cytokeratin stain using a broad spectrum antibody in all RCCs diagnosed before the age of 30. If the cytokeratin is negative or weakly and focally positive, then proceed with a TFE3 stain and/or translocation study to confirm the diagnosis. A translocation carcinoma should be suspected in adults when papillary or nested pattern carcinoma, containing very voluminous clear to eosinophilic tumor cells (with or without psammoma bodies), are present, usually within hyaline stromal nodules. We recommend doing a similar battery of immunostains for RCCs of young adults and children.

**Mucinous tubular and spindle cell carcinoma**

Mucinous tubular and spindle cell carcinoma (MTSCC) is a fairly newly described tumor which is included in the 2004 WHO classification[11]. This is a tumor defined by the presence of three histologic components: mucin, tumor cells forming tubules, and spindle cells, herein earning its appropriately descriptive name (Figure 2). This tumor occurs throughout life (age range 17-82 years) and is more
Multilocular cystic clear cell renal cell carcinoma (hematoxylin and eosin). A: The tumor is composed of multiple cysts with intervening thin, fibrous septa and scattered chronic inflammatory cells (× 40); B: On higher power, the cysts are lined by a single layer of cells with clear cytoplasm (× 200); C: Low-grade nuclear features (Fuhrman nuclear grade 1) are seen and clear cells are present within the cyst wall and on the surface lining (× 400).
RCC and papillary RCCs have also been described in neuroblastoma survivors[7,24,28]. The risk of developing another malignancy after neuroblastoma is well known[20]. RCC is the second most common type of such tumor, following thyroid carcinoma[29]. A survey of survivors of childhood cancer found a 329-fold risk of RCC in children with neuroblastoma[27]. The health risk after neuroblastoma is not limited to malignancy. A survey of 954 neuroblastoma survivors found an 8-fold likelihood of chronic health conditions, compared to their matched siblings, including musculoskeletal complications, endocrine abnormalities, and sensory abnormalities such as deafness and blindness. Many of these long-term effects are associated with treatment, which could also be associated with development of RCC[30]. However, there is evidence that the carcinoma associated with neuroblastoma is not related to therapy, but instead to an underlying genetic defect that predisposes individuals to development of cancer[25,27]. Regardless of the pathogenetic mechanism, knowledge of this entity in neuroblastoma survivors is essential for monitoring and early diagnosis.

**RECENTLY DESCRIBED TUMORS**

**Tubulocystic carcinoma**

Tubulocystic RCC is a recently described tumor composed of variably sized cystic tubules lined by a single epithelial layer with intervening fibrotic stroma (Figure 4). The neoplastic cells lining the cystic spaces have eosinophilic cytoplasm, hobnail nuclear morphology, and prominent nucleoli[28]. Tubulocystic RCC is not currently recognized by the WHO. However, accruing evidence suggests tubulocystic RCC merits consideration as a distinct entity.

Tubulocystic RCC was initially believed to derive from the collecting duct; in fact, it was originally considered a well-differentiated variant of collecting duct carcinoma. However, recent gene expression profiling evidence tends to refute this possibility[29]. The immunohistochemical staining pattern, ultrastructural features, and gene expression profiling favor a proximal convoluted tubule or intercalated cell origin[28,29]. In fact, some suggest that tubulocystic RCC may be closely related to papillary RCC[30,31]. One study of tubulocystic RCC found that 5 of their 13 cases of TCRCC had coexistent papillary renal cell neoplasms. In addition, a similar immunohistochemical staining pattern and gene expression profile between papillary RCC and TCRCC was identified[30]. This finding was supported by another study, which had 10 of 12 TCRCC cases with associated papillary neoplasms, including admixed TCRCC and papillary RCC in 4 cases[31]. This study also found gains of chromosome 17 in 8 of 12 cases of TCRCC[31]. Synchronous TCRCC with clear cell RCC has also been reported[32].

The largest clinicopathologic study to date on TCRCC was compiled by Amin et al[28] in 2009. They found TCRCC is more common in males and is a low-grade entity, with the majority of tumors presenting as stage pT1. Often, the tumor is an incidental finding. Tumors were both subcapsular (61.5%) and cortico-medullary or medullary (38.5%) in location. Only one case had local recurrence (3%) and two cases (6%) developed metastases. All cases had a Fuhrman nuclear grade of 3 despite an indolent behavior in the majority of cases, suggesting little value of Fuhrman grading in these neoplasms[28].

The differential diagnosis includes other cystic renal neoplasms, including multilocular cystic RCC. Focal cytoplasmic clearing has been noted in TCRCC[28]. Multilocular cystic clear cell RCC typically has lower Fuhrman grade nuclei, and scattered clear cells will be seen within the intervening fibrous stroma. Cystic nephroma could also be considered, but typically has larger cystic spaces and inconspicuous nucleioli. Mixed epithelial and stroma tumor also has cystic spaces, but will display an ovarian-type stroma. Oncocytoma with prominent tubules and cysts could also be considered, but typically will have nests of oncocytic cells, which are not present in TCRCC[28].

**Thyroid-like follicular carcinoma of kidney**

Thyroid-like follicular RCC was first described by Jung et al[33] in 2006. They described a case of primary renal carcinoma with morphology similar to a thyroid follicular carcinoma[33]. To date, only about 10 cases of this entity...
Renal tubular cystic changes may develop in end-stage renal disease (ESRD), and this condition is termed acquired cystic kidney disease (ACKD). Renal tumors often occur in kidneys with ESRD with or, less frequently, without ACKD. The risk of RCC in patients with ACKD is greater than 100 times that of the general population, although the incidence is less than 10%.

A prior history of dialysis is often associated with the development of ACKD and RCC, with direct correlation to duration of dialysis. The various tumor types encountered in cases with ESRD include the three common subtypes of RCC, i.e., clear cell (conventional) RCC, papillary RCC, and chromophobe RCC, with papillary RCC as the most common. However, there are at least two other subtypes of RCC that are more frequently associated with ESRD: ACKD-associated RCC and clear cell papillary RCC. ACKD-associated RCC is reported only in patients with ESRD and ACKD, thus the name; whereas clear cell papillary RCC can be seen in patients with both cystic and non-cystic ESRD, as well as in those without ESRD.

The ACKD-associated RCC is usually multifocal and bilateral. These tumors may be incidentally discovered on imaging studies or in nephrectomy specimens performed for renal cysts with complications or renal parenchymal bleeding, which not infrequently masks the underlying tumor. Most tumors are well circumscribed, and often appear to arise within cysts. Tumors which are larger in size are grossly solid with a thick, fibrous capsule and may be accompanied by foci of necrosis and hemorrhage.

Microscopically, the tumors demonstrate a growth pattern comprised of various proportions of acinar, alveolar, solid, cystic, and papillary architectural patterns. Tumor cells display characteristic features, including abundant granular, eosinophilic cytoplasm and large nuclei with prominent nucleoli (Figure 6). A cribriform or sieve-like appearance is characteristic and present in most cases. Most, but not all, cases also show intratumoral oxalate crystals, a relatively specific feature quite consistently observed in ACKD-associated RCC and not in other tumor types. Immunohistochemical stains aid in distinguishing these tumors as ACKD-associated RCC stains diffusely positive for a-methylacyl-coenzyme A racemase (AMACR), but is negative or only focally positive for CK7. Stains for CD10, RCC antigen, and glutathione S-transferase A are also reported to be positive. On a molecular level, these tumors do not show trisomy of chromosomes 7/17 or loss of 3p, characteristic of papillary and clear cell RCC, respectively. A recent study by Pan et al. on 9 cases of ACKD-associated RCC showed variable combined gains of chromosomes 3, 7, 15, 16, 17, and Y using fluorescence in situ hybridization and comparative genomic hybridization. It is also important to note that the nonneoplastic renal parenchyma often contains cysts lined by large eosinophilic cells that show an immunophenotype similar to that of ACKD.

The biologic behavior of RCCs in ESRD in general is reported to be less aggressive than that of the RCCs in non-ESRD settings. These tumors often present at a lower stage and are smaller in size. However, there are...
A few case reports with metastasis or aggressive behavior. ACD-associated RCC may have a greater potential for aggressive behavior than other tumor types in ESRD. Rare cases with sarcomatoid features and unfavorable clinical outcomes have been reported[43,48].

The exact mechanisms underlying the increased incidence of RCC in ESRD, especially in those with superimposed ACKD are not completely understood. Multiple molecular alterations in diverse types of renal tumors indicate an acquired mechanism for renal tumorigenesis. Possible precursor lesions in ESRD include papillary adenomas and dilated tubules or clustered microcystic lesions lined by the eosinophilic cells[49]. Further research is necessary in order to delineate an etiologic relationship for these tumors.

**Clear cell papillary renal cell carcinoma**

Clear cell papillary RCC is a recently recognized renal tumor. This tumor was originally described in a background of ESRD and ACKD, although it has subsequently been reported in normal kidneys[42,43,50]. Metastasis from a clear cell papillary RCC has not been reported, highlighting the likelihood that these tumors are less aggressive than other RCC subtypes[42,44,50,53].

Clear cell papillary RCC is usually small and grossly encapsulated. The tumors may be solid, white tan, pale yellow or reddish brown in external appearance; however, the typical bright or golden-yellow heterogeneous cut surface of clear cell RCC is not identified. The cystic component is usually located at the periphery of the tumor, near its junction with renal parenchyma, and may be angulated, flattened, or irregular. Bilateralism and multifocality have been documented, especially in tumors arising in a background of ACKD[42,44,50,53].

On microscopic examination, clear cell papillary RCC is composed of a varying admixture of cystic, glandular, solid, and papillary components. The tumor cells have clear cytoplasm and are usually of low nuclear grade (Fig. 7). One of the most distinctive features of clear cell papillary RCC is the linear positioning of the nuclei away from the basement membrane (inverted polarity). It is the presence of this feature within these tumors that aids in identification, irrespective of the architectural growth pattern, which can be markedly variable[43,44]. Papillary architecture is almost always present, but may be focal, and is commonly branched. Stellate tubular structures may also be seen. Some cases may have a prominent tubular pattern, as supported by previous reports describing this entity as tubulopapillary carcinoma. Other growth patterns include cystic, alveolar/nested, and retiform[43,50]. These tumors often have a fibrous capsule of varying thickness and often have variable amounts of eosinophilic hyalinized or sclerotic stroma[42,44,50,53]. Clear cell papillary RCCs sometimes contain foci of calcification or ossification, often within the tumor pseudocapsule[54].

In most cases, the morphologic features of clear cell papillary RCC are unique enough to allow for distinction from clear cell RCC based on HE-stained slides. In some
cases, immunohistochemical stains can be helpful, as clear cell papillary RCC and clear cell RCC have different immunoprofiles. Both clear cell papillary RCC and clear cell RCC typically express CA-IX, but the former usually exhibits weak expression, which is localized to the basal and lateral aspects of the tumor cells, so-called cup-shaped expression[44]. CD10 and 34BE12 show variable expression in these 2 tumor types, with the former more frequently positively expressed in clear cell papillary RCC. CK7 appears to be the most reliable marker for differentiating these 2 entities, as it is nearly always diffusely, strongly positive in clear cell papillary RCC, while only infrequently positive in clear cell RCC[43,44]. In general, when CK7 labeling is present in a clear cell RCC, it is focal or, at most, patchy and centered around cystic spaces[44]. Expression of AMACR is usually negative in both of these tumor types; thus, it is not of any use in this differential, but it can be extremely useful in cases of clear cell papillary RCC if the differential diagnosis includes papillary RCC[42,44,50-53].

Molecular changes in clear cell papillary RCC are distinctly different from those identified in clear cell and papillary RCCs. Sporadic clear cell papillary RCCs lack VHL mutations, 3p25 deletions, hypermethylation of the VHL promoter, and other recurrent copy number changes which are characteristically seen in clear cell RCCs. Of the cases reported to date, there has been only 1 VHL mutation occurring in a clear cell papillary RCC in a patient with known VHL disease, and 1 case of loss of heterozygosity of the VHL locus has been described[43]. Although low copy number gains of chromosomes 7 or 17 have been documented in a small subset of cases, the vast majority of clear cell papillary RCCs do not exhibit these findings[33,44,54,55]. No pathognomonic genetic alteration has been identified. However, a recent gene expression profile meta-analysis of clear cell RCC by Brannon et al identified 3 distinct molecular subgroups within clear cell RCC. One of these groups corresponded to a VHL wild-type pattern of gene expression and, from the images provided in the article, morphologically appears to represent clear cell papillary RCC. This study highlights the fact that many clear cell papillary RCCs were incorrectly diagnosed as clear cell RCC in the past, while also emphasizing that clear cell papillary RCC and clear cell RCC are distinct entities.

CANDIDATE ENTITIES

RCC with t(6;11) translocation

An extremely rare subset of renal translocation tumors is associated with t(6;11) (p21;q12)/Alpha-TFEB gene fusion. This distinctive tumor was first described by Araghi et al in 2001. Since then, a handful of cases of this rare entity have been documented in the literature. TFEB RCCs are predominantly seen in younger patients and are generally indolent, with rare reported cases of metastatic disease[58-66]. The most common histologic pattern is large epithelioid cells with voluminous clear to slightly eosinophilic cytoplasm, and clusters of small cells, usually clustered around hyaline material (rosette-forming) (Figure 8). However, TFEB RCCs may demonstrate unusual morphologic features, such as papillary, tubular, chromophobe RCC, clear cell RCC, and epithelioid angiomylipoma-like structures[38-40].

A recently developed antibody to TFEB and cathep-
TFEB and HMB45 immunostains are recommended to stain is recommended. If the TFE3 stain is negative, or weakly to focally positive, a TFE3 tumor in young patients under 30. If the initial cytokeraapproach of immunostains as for Xp11 translocation carcinomato determine long-term clinical outcomes.

indolent tumor. However, further studies are warranted available were alive with no recurrent disease. Their fol
testifying regarding the final clinical outcome of patients.

indicates that there must be nuclear positivity for TFEB, as the fusion product will be present in the nucleus. Non-translocated TFEB can cause falsely positive cytoplasmic staining\(^\text{[58]}\). Both TFEB and TFE3 (described above in Xp11 translocation RCC) are part of the microphthalmia transcription factor/transcription factor family translocation RCCs. Overexpression of TFEB and TFEB in these neoplasms is known to increase the expression of cathepsin K proteins\(^\text{[58]}\). A study by Martignoni et al\(^\text{[67]}\) showed that 7 of 7 TFEB RCC and 6 of 10 Xp11 translocation RCC had strong expression of cathepsin K, which was not seen in any other renal neoplasms\(^\text{[58]}\). In the study by Rao et al\(^\text{[66]}\), all of the tumors showed moderate to strong immunoreactivity for TFEB, Ksp-cadherin, and vimentin, but were negative for TFE3, CD10, and CK7. Cathepsin K, HMB45, and melan A are moderately or strongly expressed in TFEB RCCs\(^\text{[58-67]}\).

TFEB RCCs are often diagnosed based upon their distinctive morphology and immunophenotype. However, molecular methods such as PCR, RT-PCR, and FISH are extremely helpful and sometimes mandated for an accurate diagnosis. An interphase FISH assay is useful in the definitive identification of TFEB RCCs, and plays an essential role in identifying previously undiagnosed cases\(^\text{[66,68]}\).

As these are rare tumors, there is still a degree of uncertainty regarding the final clinical outcome of patients. In the study by Rao et al\(^\text{[66]}\), all 6 patients with follow-up available were alive with no recurrent disease. Their follow-up ranged from 6 to 55 mo, with a mean follow-up time of 31 mo. Other studies have shown a similar good prognosis\(^\text{[69,70]}\), and TFEB RCC appears to be a relatively indolent tumor. However, further studies are warranted to determine long-term clinical outcomes.

To detect this tumor, we recommend the same approach of immunostains as for Xp11 translocation carcinoma in young patients under 30. If the initial cytokeratin stain is negative or weakly to focally positive, a TFE3 stain is recommended. If the TFE3 stain is negative, TFEB and HMB45 immunostains are recommended to diagnose a RCC with t(6;11) translocation tumor (both TFEB and HMB45 positive), and exclude the possibility of epithelioid angiomylolipoma (TFEB negative and HMB45 positive).

### Hybrid oncocytoma/chromophobe RCC

Hybrid oncocytoma/chromophobe RCC was first recognized in patients with Birt-Hogg-Dubé (BHD) syndrome, a rare autosomal dominant condition characterized by fibrofolliculomas, renal tumors, pulmonary cysts, and spontaneous pneumothorax\(^\text{[70]}\). Mutation of the BHD gene on chromosome 17, a tumor suppressor gene, is attributed to this syndrome\(^\text{[70]}\). The renal tumors in these patients are characterized by the morphologic features of both oncocytoma and chromophobe RCC within the same tumor, known as hybrid oncocytoma/chromophobe RCC\(^\text{[70]}\). BHD patients also have an increased incidence of other RCCs, including chromophobe and clear cell RCC. The renal tumors in BHD patients are frequently bilateral and multifocal, and background renal oncocytosis within the kidney may be seen\(^\text{[70]}\). Renal oncocytosis is characterized by oncocytic change in the renal tubules and multiple oncocytomas.

Hybrid oncocytoma/chromophobe RCC has been described as occurring in patients with renal oncocytosis; however, there has been an increased recognition of this entity in sporadic tumors without a background of renal oncocytosis or BHD syndrome\(^\text{[71,72]}\). These tumors are composed of cells with abundant granular eosinophilic cytoplasm, round nuclei, perinuclear halos, and CK7 positivity (Figure 9). Some of these sporadic hybrid tumors have distinctly different morphology in separate areas, while others have mixed features throughout\(^\text{[71]}\).

The heightened awareness of hybrid tumors leads to questions of the utility of core needle biopsy in oncocytic neoplasms, which may miss a chromophobe component in a hybrid tumor due to sampling error. The distinction between oncocytoma and chromophobe RCC is clinically important, and the behavior of these hybrid entities is yet unknown. However, small, retrospective studies have
shown that these hybrid oncocytoma/chromophobe tumors have a clinically indolent course[73]. Further studies are needed to determine the behavior and pathogenesis of these neoplasms.

**Hereditary leiomyomatosis and RCC syndrome**

Hereditary leiomyomatosis and RCC (HLRCC) is an autosomal dominant familial syndrome characterized by the development of cutaneous and uterine leiomyomatous, as well as renal tumors[74]. The hallmark mutation in this syndrome is the fumarate hydratase (FH, 1q42.3-q43) gene, but the exact prevalence of HLRCC is unknown. Kidney cancers are less penetrant than the leiomyomatous manifestations in HLRCC-affected families[75,77]. The association between cutaneous and uterine leiomyomatous has been known for many years as Reed syndrome[78].

The renal tumors in this syndrome are aggressive, as demonstrated by the fact that 9 out of 13 patients in the first reported cohort of North American families died of metastatic disease within 5 years of initial diagnosis[79]. Other studies have shown lymph node metastasis is common, and there is a poor prognosis[80]. In the largest series published by Merino et al[80], 40 renal tumors resected from 38 HLRCC patients with proven fumarate hydratase germline mutations were studied. The patient age ranged from 17 to 75 years and tumors ranged in size from 2.3 to 20 cm. A papillary architecture was most common (25 of 40 cases), but tubulopapillary, tubular, solid, and mixed patterns were also seen. Immunohistochemical stains were nonspecific. The defining characteristic of HLRCC, as described by Merino et al[80], is the presence of a large nucleus with a prominent inclusion-like eosinophilic nucleolus, surrounded by a perinucleolar clearing. This distinctive morphology is also seen in the leiomyomatous of these patients (described below).

Leiomyomatosis is a condition defined by the occurrence of multiple leiomyomas throughout the body, with often poorly defined nodules involving areas of the skin on the arms, chest, legs, and, in extremely rare cases, the uterus. In a study by Sanz-Ortega et al[81], uterine leiomyomatous were identified in HLRCC patients at a young age (median age of 32 years). They were often multiple and ranged from 1 to 8.5 cm in size. Histopathologically, HLRCC leiomyomata frequently had increased cellularity, multinucleated cells, and atypia. All cases showed tumor nuclei with large orangephilic nuclei surrounded by a perinucleolar halo similar to the changes found in HLRCC[79]. This study also showed that loss of heterozygosity (LOH) at 1q43 was frequent in HLRCC leiomyomas (8/10 cases), similar to the molecular alterations in renal tumors. LOH is considered to be the second hit that inactivates the FH gene, and FH mutations and LOH at 1q43 are unusual in sporadic leiomyomas.

Uterine leiomyomas and renal tumors in HLRCC share similar morphologic changes and genotypic features. It is important to recognize these features in leiomyomata so patients undergo early genetic testing for germline FH mutations and screening for renal cell cancer.

**Renal angiomyoadenomatous tumor**

Michal et al[81] reported a series of 5 cases which they designated as renal angiomyoadenomatous tumor, wherein the tumors were composed of clear cells, leiomyomatous stroma, and adenomatous structures with apical snouting (described as resembling a “shark’s smile”) (Figure 10). The epithelial tumor cells were positive for EMA, CK7, CK20, AE1-AE3, CAM5.2, and vimentin. In this series of cases, no VHL mutation was identified.

Cases of clear cell papillary RCC with smooth muscle metaplasia of intratumoral stroma, also recently described as “RCC with angioleiomyoma-like proliferation” or “clear cell RCC with smooth muscle stroma”, share a significant degree of morphologic overlap with this entity[80,83]. It is currently debated whether these two tumors are related, or perhaps even variants of the same tumor[84-88]. Losses of chromosome 3 and 3p have been demonstrated in at least a subset of these tumors[83]. Some studies report that these lesions have demonstrated abnormalities of chromosomes 3 and the VHL gene, in addition to abnormalities of chromosomes 1, 11, and 16[83,85,86,88].

**CONCLUSION**

Our understanding of RCC continues to evolve. The
review of recent updates in selected tumors herein will hopefully serve as a useful prognostic and treatment guide for both the urologist and surgical pathologist, particularly in the era of personalized medicine.

ACKNOWLEDGEMENTS

The authors would like to acknowledge Dr. Pheroze Tamboli, Dr. Liang Cheng, and Dr. Melissa Stanton for their assistance with photographs for the manuscript. They would also like to acknowledge Philip Randall and Linne Girouard for their assistance with editing and formatting.

REFERENCES

1 Argani P, Ladanyi M. Renal carcinomas associated with Xp11.2 translocations/TFE3 gene fusions. In: Eble J, Sauter G, Epstein J, Sesterhenn I. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press, 2004: 37
2 Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med 2005; 25: 363-378 [PMID: 15848741 DOI: 10.1016/j.cll.2005.01.008]
3 Armah HB, Parwani AV. Xp11.2 translocation renal cell carcinoma. Arch Pathol Lab Med 2010; 134: 124-129 [PMID: 20073616 DOI: 10.1043/2008-0591-8SR.1]
4 Shen SS, Truong LD, Ayala AG, Ro JY. Recently described and emphasized entities of renal neoplasms. Arch Pathol Lab Med 2007; 131: 1234-1243 [PMID: 17683186]
5 Argani P, Olgač S, Tickoo SK, Goldfischer M, Moch H, Chan DY, Eble JN, Bonsib SM, Jimeno M, Lloreta J, Billis A, Hicks J, De Marzo AM, Reuter VE, Ladanyi M. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007; 31: 1149-1160 [PMID: 17667536 DOI: 10.1097/PAS.0b013e318031fffe]
6 Suzigan S, Drut R, Faria P, Argani P, De Marzo AM, Barbosa RN, Mello Denadai ER, Martins-Filho J, Martucci RC, Bauab T. Xp11 translocation carcinoma of the kidney presenting with multicystic cystic renal cell carcinoma-like features. Int J Surg Pathol 2007; 15: 199-203 [PMID: 17478783 DOI: 10.1177/1066896906295891]
7 Argani P, Cai D, Ballard ET, Amin M, Manivel C, Hutchinson B, Reuter VE, Ladanyi M. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol 2006; 24: 1529-1534 [PMID: 16575003 DOI: 10.1200/JCO.2005.04.4693]
8 Klatte T, Streubel B, Wrba F, Remzi M, Krammer B, de Martinino M, Walldert M, Marberger M, Susani M, Haitel A. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol 2012; 137: 761-768 [PMID: 22523215 DOI: 10.1309/AJCQP64LFLM40XGC]
9 Zhong M, De Angelo P, Osborne L, Paniz-Mondolfi AE, Geller M, Yang Y, Linehan WM, Merino MJ, Cordon-Cardo C, Cai D. Translocation renal cell carcinomas in adults: a single-institution experience. Am J Surg Pathol 2012; 36: 654-662 [PMID: 22446944 DOI: 10.1097/PAS.0b013e31824f24a6]
10 Klaassen Z, Tatem A, Burnette JO, Donohoe JM, Terris MK. Adult Xp11 translocation associated renal cell carcinoma: time to recognize. Urolodgy 2012; 80: 965-968 [PMID: 22999449 DOI: 10.1016/j.urology.2012.07.051]
11 Srigley J. Mucinous Tubular and Spindle Cell Carcinoma. In: Eble J, Sauter G, Epstein J, Sesterhenn I. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004: 40
12 Paner GP, Srigley JR, Radhakrishnan A, Cohen C, Skinnider BP, Tickoo SK, Young AN, Amin MB. Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol 2006; 30: 13-19 [PMID: 16330977]
13 Shen SS, Ro JY, Tamboli P, Truong LD, Zhai Q, Jung SJ, Tibbs RG, Ordonez NG, Ayala AG. Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features. Ann Diagn Pathol 2007; 11: 13-21 [PMID: 17240302 DOI: 10.1016/j.amediagpath.2006.09.005]
14 Cossu-Rocca F, Eble JN, Delahunt B, Zhang S, Martignoni G, Brunelli M, Cheng L. Renal mucinous tubular and spindle cell carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Mod Pathol 2006; 19: 488-493 [PMID: 16554730 DOI: 10.1038/modpathol.3800565]
15 Brandal P, Lie AK, Bassarova S, Svinland A, Risberg B, Danielsen H, Heim S. Genomic aberrations in mucinous tubular and spindle cell renal cell carcinomas. Mod Pathol 2006; 19: 186-194 [PMID: 16258504 DOI: 10.1038/modpathol.3800499]
16 Fine SW, Argani P, DeMarzo AM, Delahunt B, Sebo TJ, Reuter VE, Epstein JL. Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma. Am J Surg Pathol 2006; 30: 1554-1560 [PMID: 17122511 DOI: 10.1097/01.pas.0000213271.15221.e3]
17 Dhillion J, Amin MB, Selby E, Turi GK, Paner GP, Reuter VE. Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol 2009; 33: 44-49 [PMID: 18941398 DOI: 10.1097/PAS.0b013e3181829ed5]
18 Ebbe J. Multicystic renal cystic cell carcinoma. In: Eble J, Sauter G, Epstein J, Sesterhenn I. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004: 26
19 Williamson SR, Halat S, Eble JN, Grignon DJ, Lopez-Beltran A, Montironi R, Tan PH, Wang M, Zhang S, MacLennan GT, Baldridge LA, Cheng L. Multicystic renal cystic cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma. Am J Surg Pathol 2012; 36: 1425-1433 [PMID: 22982885 DOI: 10.1097/PAS.0b013e3182b53760]
20 Halat S, Eble JN, Grignon DJ, Lopez-Beltran A, Montironi R, Tan PH, Wang M, Zhang S, MacLennan GT, Cheng L. Multicystic renal cystic cell carcinoma is a subtype of clear cell renal cell carcinoma. Mod Pathol 2010; 23: 931-936 [PMID: 20348877 DOI: 10.1038/modpathol.2010.78]
21 Suzigan S, Lopez-Beltran A, Montironi R, Drut R, Romero A, Hayashi T, Gentili AL, Fonseca PS, de Torres I, Billis A, Japp JC, Bollito E, Algaba F, Requena-Tapias MJ. Multicystic renal cystic cell carcinoma: a report of 45 cases of a kidney tumor of low malignant potential. Am J Clin Pathol 2006; 125: 217-222 [PMID: 16393684 DOI: 10.1309/AH6F-C77P-YR2V-6AY]
22 Medeiros L. Renal cell carcinoma associated with neuroblastoma. In: Eble J, Sauter G, Epstein J, Sesterhenn I. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004: 39
23 Medeiros LJ, Palmedo G, Buckingham JB. Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity. Am J Surg Pathol 1999; 23: 772-780 [PMID: 10430299]
24 Hedgepeth RC, Zhou M, Ross J. Rapid development of metastatic Xp11 translocation renal cell carcinoma in a girl treated for neuroblastoma. J Pediatr Hematol Oncol 2009; 31: 602-604 [PMID: 1963626 DOI: 10.1097/MPH.0b013e3181d9f81]
25 Altinok G, Kattar MM, Mohmed A, Poulik J, Grignon D, Rabah R. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations. Pediatr Dev Pathol 2005; 8: 168-180 [PMID: 16554730 DOI: 10.1038/modpathol.3800565]

Crumley SM et al. Renal cell carcinoma
Renal cell carcinoma

a pathologic analysis. *Kidney Int* 2002; 61: 2201-2209 [PMID: 12082461 DOI: 10.1046/j.1523-1755.2002.00374.x]

39 Choyke PL. Acquired cystic kidney disease. *Eur Radiol* 2000; 10: 1716-1721 [PMID: 11097395]

40 Doubilet JD, Paradis MN, Gatgebno G, Thibault P, Scaer JD. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. *J Urol* 1997; 158: 42-44 [PMID: 9186319 DOI: 10.1097/00005392-199707000-00012]

41 Hughson MD, Buchwald D, Fox M. Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis. *Arch Pathol Lab Med* 1986; 110: 592-601 [PMID: 3521533]

42 Tickoo SK, dePeralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moih H, Amin MB. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. *Am J Surg Pathol* 2006; 30: 141-153 [PMID: 16434887]

43 Aydin H, Chen L, Cheng L, Vaziri S, He H, Ganapathi M, Diller LR, Cheung NK, Wolden S, Robison LL, Sklar CA. Renal cell carcinoma: implications for pathologic classification. *Arch Pathol Lab Med* 2010; 134: 1606-1621 [PMID: 20924276 DOI: 10.1097/PAL.0b013e3181ee0688]

44 Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Alhmadia HA, Fine SW, Gopalan A, Reuter VE, Rosenblum MK, Russo P, Tickoo SK. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. *Mod Pathol* 2011; 24: 1207-1220 [PMID: 21602815 DOI: 10.1038/modpathol.2011.80]

45 Sule N, Yakupoglu U, Shen SS, Krishnan B, Yang G, Lerner S, Sheikh-Hamad D, Truong LD. Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. *Am J Surg Pathol* 2005; 29: 443-451 [PMID: 15767796]

46 Pan CC, Chen YJ, Chang LC, Chang YH, Ho DM. Immunohistochemical and molecular genetic profiling of acquired cystic disease-associated renal cell carcinoma. *Histopathology* 2009; 55: 145-153 [PMID: 19694821 DOI: 10.1111/j.1365-2559.2009.03361.x]

47 Ishikawa I, Saito Y, Asaka M, Tomosugi N, Yuri T, Watanabe M, Honda R. Twenty-year follow-up of acquired renal cystic disease. *Clin Nephrol* 2003; 59: 153-159 [PMID: 12653526]

48 Kuroda N, Tamura M, Taguchi T, Tomimaga A, Hes O, Michal M, Ohara M, Hiouchi T, Mizuno K, Hayashi Y, Shuin T, Lee GH. Sarcomatoid acquired cystic kidney disease: a comprehensive study. *Histol Histopathol* 2008; 23: 1327-1331 [PMID: 18785115]

49 Chen YB, Tickoo SK. Spectrum of preneoplastic and neoplastic cystic lesions of the kidney. *Arch Pathol Lab Med* 2012; 136: 400-409 [PMID: 22458902 DOI: 10.5888/arpa.2011-0485-RA]

50 Gobbo S, Ebe JN, Grignon DJ, Martignoni G, MacLennan GT, Shah RB, Zhang S, Brunelli M, Cheng L. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. *Am J Surg Pathol* 2008; 32: 1239-1245 [PMID: 18594469 DOI: 10.1097/PAS.0b013e318164bbcb]

51 Adam J, Couturier J, Molinié V, Vieilledon A, Sibony M. Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases. *Histopathology* 2011; 58: 1064-1071 [PMID: 21707708 DOI: 10.1111/j.1365-2559.2011.09387.x]

52 Bhatnagar R, Alexiev BA. Renal cell carcinomas in end-stage kidneys: a clinicopathological study with emphasis on clear-cell papillary renal-cell carcinoma and acquired cystic kidney disease-associated carcinoma. *Int J Surg Pathol* 2012; 20: 19-28 [PMID: 21791489 DOI: 10.1177/1066896911414273]
Williamson SR, Eble JN, Cheng L, Grignon DJ. Clear cell papillary renal cell carcinoma: differential diagnosis and extended immunohistochemical profile. Mod Pathol 2013; 26: 697-708 [PMID: 23220627 DOI: 10.1038/modpathol.2012.204]

Inoue T, Matsui K, Yoshimoto T, Nguyen LT, Tsukamoto Y, Nakada C, Hijiya N, Narimatsu T, Nomura T, Sato F, Nagashima Y, Kashi ma H, Katakayama S, Ohyama C, Numakura K, Habuchi T, Nakagawa M, Seto M, Mimata H, Moriya M. Genomic profiling of clear renal cell carcinoma in patients with end-stage renal disease. Cancer Sci 2012; 103: 569-576 [PMID: 22145865 DOI: 10.1111/j.1440-7388.2011.07217.x]

Wolfe A, Dobin SM, Grossmann P, Michal M, Donner LR. Clonal trisomies 7, 10 and 12, normal 3p and absence of VHL gene mutation in a clear cell tubulopapillary carcinoma of the kidney. Virchows Arch 2011; 459: 457-463 [PMID: 21822660 DOI: 10.1007/s00428-011-1137-3]

Brannon AR, Haake SM, Hacker KE, Prutti RS, Wallen EM, Nielsen ME, Rathmell WK. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol 2012; 61: 258-268 [PMID: 22030199 DOI: 10.1016/j.ejuro.2011.10.007]

Argani P, Hawkins A, Griffin CA, Goldstein JD, Haas M, Beckwith JB, Mankinen CB, Perlman EJ. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 2001; 158: 2089-2096 [PMID: 11395386 DOI: 10.1016/S0002-9440(10)66680-9]

Argani P, Laë M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, Tomaszewski JE, Brooks JS, Acs G, Bridge JA, Vargas SO, Davis IJ, Fisher DE, Ladanyi M. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol 2005; 29: 230-240 [PMID: 15644781]

Hora M, Hes O, Lërge T, Eret V, Klecka J, Michal M. A distinct translocation carcinoma of the kidney ["rosette-like forming," t(6;11), HMB45-positive renal cell carcinoma]. Int Urol Nephrol 2009; 41: 553-557 [PMID: 18998233 DOI: 10.1007/s11255-008-9495-8]

Imamura K, Fujivara M, Togashi Y, Nomura K, Mukai H, Fujiyama K, Yamamoto S, Yonese J, Fukui I, Ishikawa Y. Diverse fusion patterns and heterogeneous clinico pathological features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol 2012; 36: 35-42 [PMID: 22173116 DOI: 10.1097/PAS.0b013e3182293ec3]

Pecciarini L, Camparo P, Vasiliiu V, Molinie V, Couturier J, Dykema S1, Crumley SM, Petersson F, Schmidbauer K, Yonescu R, Morsberger L, Morris K, Netto GJ, Klatte T, Haitel A, Ozsoy M, Schmidbauer K, Vaněček T, Michal M, Martignoni G, Brunelli E, Haake SM, Hacker KE, Pruthi RS, Wallen ED, Zhan HQ, Wang CF, Zhu XZ, Xu XL. Renal cell carcinoma with t(6;11) translocation: a patient case with a novel Alpha-TFEB fusion point. J Clin Oncol 2010; 28: e709-e713 [PMID: 20823414 DOI: 10.1200/JCO.2010.30.3172]

Rao Q, Liu B, Cheng L, Zhu Y, Shi QL, Wu B, Jiang SJ, Wang Y, Wang X, Yu B, Zhang RS, Ma HH, Lu ZF, Tu P, Wang JD, Zhou XJ. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphologic, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol 2012; 36: 1327-1338 [PMID: 22895266 DOI: 10.1097/PAS.0b013e31822aaf58]

Martignoni G, Pea M, Gobbo S, Brunelli F, Bonetti F, Segala D, Pan CC, Netto G, Doglioni C, Hes O, Argani P, Chibosi M. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol 2009; 22: 1016-1022 [PMID: 19396149 DOI: 10.1038/modpathol.2009.58]

Zhang H, Wang F, Wang N, Brown S, Zhan HQ, Wang J, Mu D, Kim Y, Zheng Y, Chen L, Tang W, Wang Z, Wang X, Yu B, Jiang SJ, Wang Y, Wang X, Yu B, Zhang RS, Ma HH, Lu ZF, Tu P, Wang JD, Zhou XJ. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphologic, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol 2012; 36: 1327-1338 [PMID: 22895266 DOI: 10.1097/PAS.0b013e31822aaf58]

Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, Merino MJ. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 2002; 26: 1542-1552 [PMID: 12459621]

Linehan WM, Pinto PA, Bratslavsky G, Paffenroth E, Merino M, Vocke CD, Toro JR, Bottaro D, Ne ckers L, Schmidt LS, Srivin asan R. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 2009; 115: 2252-2261 [PMID: 19402075 DOI: 10.1002/cncr.24230]

Petersson F, Cattalica Z, Grossmann P, Perez Montiel MD, Alvarezo Cabero I, Bulimbasic S, Sweatek A, Straka L, Tichy T, Hora M, Kuroda N, Legendre B, Michal M, Hes O. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch 2010; 456: 355-365 [PMID: 20300772 DOI: 10.1007/s00428-010-0898-4]

Delongchamps NB, Galmiche L, Eiss D, Rouach Y, Vogt B, Timis MO, Vieillefond A, Mlejnek A. Hybrid tumor 'oncocytoma-chromophobe renal cell carcinoma' of the kidney: a report of seven sporadic cases. BJU Int 2009; 103: 1381-1384 [PMID: 19154947 DOI: 10.1111/j.1440-1617.2008.07263.x]

Walder M, Klatte T, Haitel A, Ozsoy M, Schmidbauer J, Marberger M, Renzi M. Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol 2010; 57: 661-665 [PMID: 19477583 DOI: 10.1016/j.eururo.2009.05.009]

Launonen V, Vierimaa O, Kiiuru M, Isola J, Roth S, Pukkala E, Vainio H, Herva R, Aaltonen LA. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001; 98: 3387-3392 [PMID: 11248088 DOI: 10.1073/pnas.011633798]

Torro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, Stewart L, Duray P, Tourre O, Sharma N, Choyke P, Stratton P, Merino M, Walther MM, Linehan WM, Schmidt LS, Zbar B. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell can-
Tomlinson IP, Alam NA, Rowan AJ, Barclay EA, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Villkki S, Laiho P, Eklund C, Vilkki S, Aittomäki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat Genet* 2002; 30: 406-410 [PMID: 11865300 DOI: 10.1038/ng849]

72. Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, Choyke P, Grubb R, Middelton L, Turner ML, Walker RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Laiho P, Eklund C, Vilkki S, Aittomäki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat Genet* 2002; 30: 406-410 [PMID: 11865300 DOI: 10.1038/ng849]

73. Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. *Acta Derm Venereol* 1973; 53: 409-416 [PMID: 4127477]

74. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome. *J Med Genet* 2006; 43: 18-27 [PMID: 15937070 DOI: 10.1136/jmg.2005.033506]

75. Sano-Otsgaard J, Vocke C, Stratton P, Linehan WM, Merino MJ. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. *Am J Surg Pathol* 2013; 37: 74-80 [PMID: 23211287 DOI: 10.1097/PAS.0b013e31825e16f]

76. Michal M, Hes O, Nemcova J, Sima R, Kuroda N, Bulimbasic S, Franco M, Sakaia N, Danis D, Kazakov DV, Ohe C, Hora M. Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity. *Virchows Arch* 2009; 454: 89-99 [PMID: 19020896 DOI: 10.1007/s00428-008-0697-3]

77. Kuhn E, De Anda J, Manoni S, Netto G, Rosai J. Renal cell carcinoma associated with prominent angioleiomyoma-like proliferation: Report of 5 cases and review of the literature. *Am J Surg Pathol* 2006; 30: 1372-1381 [PMID: 17063076 DOI: 10.1097/01.pas.0000213277.45715.82]

78. Shannon BA, Cohen RJ, Segal A, Baker EG, Murch AR. Clear cell renal cell carcinoma with smooth muscle stroma. *Hum Pathol* 2009; 40: 425-429 [PMID: 18789480 DOI: 10.1016/j.humpath.2008.05.021]

79. Michal M, Hes O, Kuroda N, Kazakov DV, Hora M. Difference between RAT and clear cell papillary renal cell carcinoma/renal cell carcinoma. *Virchows Arch* 2009; 454: 719 [PMID: 19471960 DOI: 10.1007/s00428-009-0788-9]

80. Kuroda N, Hosokawa T, Michal M, Hes O, Sima R, Ohe C, Lee GH. Clear cell renal cell carcinoma with focal renal angiomyoadenomatous tumor-like area. *Ann Diagn Pathol* 2011; 15: 202-206 [PMID: 20952290 DOI: 10.1016/j.anndiagpath.2010.03.003]

81. Kuroda N, Michal M, Hes O, Taguchi T, Tominaga A, Mizobuchi K, Ohe C, Sakaia N, Uemura Y, Shuin T, Lee GH. Renal angiomyoadenomatous tumor: fluorescence in situ hybridization. *Pathol Int* 2009; 59: 689-691 [PMID: 19712141 DOI: 10.1111/j.1440-1827.2009.02429.x]

82. Petersson F, Yan B, Huang J, Thamboo TP, Bing TK, Consigliere DT. Low-grade renal carcinoma with histologic features overlapping with renal angiomyoadenomatous tumor and featuring polysomy 7 and 17 and a mutation in the von Hippel-Lindau gene: a report of a hybrid tumor and a few comments on renal angiomyoadenomatous tumor and papillary renal tumors with clear cells. *Ann Diagn Pathol* 2011; 15: 213-216 [PMID: 21398664 DOI: 10.1016/j.anndiagpath.2010.1.005]

83. Verine J. Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity. *Virchows Arch* 2009; 454: 479-480 [PMID: 19205727 DOI: 10.1007/s00428-009-0741-y]

P- Reviewers: Kim SH, Shoji S  S- Editor: Zhai HH  L- Editor: A  E- Editor: Yan JL
